Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech
Abstrakt
A total of 83 triple-class exposed relapsed/refractory multiple myeloma patients who initiated any subsequent therapy were identified from the Czech Registry of Monoclonal Gammopathies. Patients had median overall survival of 14.2 months, progression free survival 6.2 months, and time to next treatment 7.2 months.
These results show high disease burden and are in line with results from other studies. Background: Although novel therapies improved prognosis of multiple myeloma (MM) patients, clinical outcomes in the multi-refractory population are still poor.
Patients and Methods: We reviewed data from the Czech Registry of Monoclonal Gammopathies, identified and characterized triple-class exposed (3CE) relapsed/refractory MM patients, treatment patterns after 3CE, assessed overall survival (OS), progression-free survival (PFS), time to next treatment (TTNT), explored cohorts with and without triple-and penta-refractoriness. Results: In 83 3CE patients who started subsequent therapies, the median OS was 14.2 months (95% CI, 8.5-19.9), PFS 6.2 months (95% CI, 3.9-8.5), and TTNT 7.2 months (95% CI, 4.6-9.8).
Triple-and penta-class refractory patients had a significantly worse prognosis in all outcomes. Their life expectancy was shorter, the disease progression started earlier, and the TTNT was shorter, which increased likelihood of becoming refractory to more therapies.
Time-to-event results from the first index date and all index dates analyses were very similar. Conclusion: Similar to previous studies from the US and Europe, our results show a high disease burden.
Introduction of novel therapies, such as CAR-T cells, new bispecific and trispecific monoclonal antibodies, and other drugs, is expected to bring significant benefits to these patients.